Literature DB >> 29661938

Dual functionality of β-tryptase protomers as both proteases and cofactors in the active tetramer.

Henry R Maun1, Peter S Liu2, Yvonne Franke3, Charles Eigenbrot4, William F Forrest5, Lawrence B Schwartz6, Robert A Lazarus7.   

Abstract

Human β-tryptase, a tetrameric trypsin-like serine protease, is an important mediator of the allergic inflammatory responses in asthma. During acute hypersensitivity reactions, mast cells degranulate, releasing active tetramer as a complex with proteoglycans. Extensive efforts have focused on developing therapeutic β-tryptase inhibitors, but its unique activation mechanism is less well-explored. Tryptase is active only after proteolytic removal of the pro-domain followed by tetramer formation via two distinct symmetry-related interfaces. We show that the cleaved I16G mutant cannot tetramerize, likely due to impaired insertion of its N terminus into its "activation pocket," indicating allosteric linkage at multiple sites on each protomer. We engineered cysteines into each of the two distinct interfaces (Y75C for small or I99C for large) to assess the activity of each tetramer and disulfide-locked dimer. Using size-exclusion chromatography and enzymatic assays, we demonstrate that the two large tetramer interfaces regulate enzymatic activity, elucidating the importance of this protein-protein interaction for allosteric regulation. Notably, the I99C large interface dimer is active, even in the absence of heparin. We show that a monomeric β-tryptase mutant (I99C*/Y75A/Y37bA, where C* is cysteinylated Cys-99) cannot form a dimer or tetramer, yet it is active but only in the presence of heparin. Thus heparin both stabilizes the tetramer and allosterically conditions the active site. We hypothesize that each β-tryptase protomer in the tetramer has two distinct roles, acting both as a protease and as a cofactor for its neighboring protomer, to allosterically regulate enzymatic activity, providing a rationale for direct correlation of tetramer stability with proteolytic activity.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  allosteric regulation; enzyme mechanism; heparin-binding protein; protein engineering; protein–protein interaction; serine protease; tetramerization; tryptase

Mesh:

Substances:

Year:  2018        PMID: 29661938      PMCID: PMC6016454          DOI: 10.1074/jbc.M117.812016

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  69 in total

1.  Heparin makes differences: a molecular dynamics simulation study on the human βII-tryptase monomer.

Authors:  Yan Wang; Qing-Chuan Zheng; Chui-Peng Kong; Ye Tian; Jiuyu Zhan; Ji-Long Zhang; Hong-Xing Zhang
Journal:  Mol Biosyst       Date:  2014-11-04

Review 2.  Mast cell-restricted tryptases: structure and function in inflammation and pathogen defense.

Authors:  H Patrick McNeil; Roberto Adachi; Richard L Stevens
Journal:  J Biol Chem       Date:  2007-05-15       Impact factor: 5.157

3.  A novel heparin-dependent processing pathway for human tryptase. Autocatalysis followed by activation with dipeptidyl peptidase I.

Authors:  K Sakai; S Ren; L B Schwartz
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

4.  Immunologic and physicochemical evidence for conformational changes occurring on conversion of human mast cell tryptase from active tetramer to inactive monomer. Production of monoclonal antibodies recognizing active tryptase.

Authors:  L B Schwartz; T R Bradford; D C Lee; J F Chlebowski
Journal:  J Immunol       Date:  1990-03-15       Impact factor: 5.422

5.  Zymogen activation in the streptokinase-plasminogen complex. Ile1 is required for the formation of a functional active site.

Authors:  S Wang; G L Reed; L Hedstrom
Journal:  Eur J Biochem       Date:  2000-07

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

Review 7.  Active monomers of human beta-tryptase have expanded substrate specificities.

Authors:  Yoshihiro Fukuoka; Lawrence B Schwartz
Journal:  Int Immunopharmacol       Date:  2007-07-27       Impact factor: 4.932

8.  Inactivation of human high molecular weight kininogen by human mast cell tryptase.

Authors:  M Maier; J Spragg; L B Schwartz
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

Review 9.  Mast cell glycosaminoglycans.

Authors:  B Mulloy; R Lever; C P Page
Journal:  Glycoconj J       Date:  2016-11-30       Impact factor: 2.916

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  3 in total

1.  Impact of naturally forming human α/β-tryptase heterotetramers in the pathogenesis of hereditary α-tryptasemia.

Authors:  Quang T Le; Jonathan J Lyons; Andrea N Naranjo; Ana Olivera; Robert A Lazarus; Dean D Metcalfe; Joshua D Milner; Lawrence B Schwartz
Journal:  J Exp Med       Date:  2019-07-23       Impact factor: 14.307

2.  Bivalent antibody pliers inhibit β-tryptase by an allosteric mechanism dependent on the IgG hinge.

Authors:  Henry R Maun; Rajesh Vij; Benjamin T Walters; Ashley Morando; Janet K Jackman; Ping Wu; Alberto Estevez; Xiaocheng Chen; Yvonne Franke; Michael T Lipari; Mark S Dennis; Daniel Kirchhofer; Claudio Ciferri; Kelly M Loyet; Tangsheng Yi; Charles Eigenbrot; Robert A Lazarus; James T Koerber
Journal:  Nat Commun       Date:  2020-12-22       Impact factor: 14.919

Review 3.  Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond.

Authors:  Bettina Sprinzl; Georg Greiner; Goekhan Uyanik; Michel Arock; Torsten Haferlach; Wolfgang R Sperr; Peter Valent; Gregor Hoermann
Journal:  Int J Mol Sci       Date:  2021-02-28       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.